What You Should Know:
– Noom, a digital healthcare company, is shaking up the weight loss industry with the launch of Noom GLP-1Rx, an innovative program offers affordable, accessible, and sustainable weight loss by combining compounded GLP-1 injections with Noom’s proven behavioral change program.
– Noom GLP-1Rx delivers highly efficacious medications to the door within seven days starting at $149 and pairs those powerful medications with Noom GLP-1 Companion with Muscle Defense.
The Obesity Crisis and GLP-1 Medications
Obesity is a major public health concern in the United States, affecting over 42% of the population. GLP-1 medications have emerged as a powerful tool for weight loss, but access and affordability remain significant barriers.
- High Costs: Brand-name GLP-1 medications come at a premium, with prices reaching $1,349 per month in the US compared to significantly lower costs in other countries.
- Limited Availability: Drug shortages are a recurring issue, leaving many patients unable to access their prescriptions.
Noom GLP-1Rx: Addressing the Challenges
Noom GLP-1Rx tackles these challenges head-on:
- Affordable Access: Noom offers compounded semaglutide, the same active ingredient found in brand-name medications, at a lower cost.
- Convenient Delivery: Medications are delivered directly to a patient’s door within seven days.
- Physician Consultation: Noom members are evaluated by board-certified obesity experts before qualifying for the program.
- FDA-Regulated Quality: Medications are sourced from an FDA-regulated 503B compounding pharmacy, ensuring the highest standards of safety and effectiveness.
The Noom Taper-Off Guarantee
Noom recognizes the importance of long-term weight management. With the Noom Taper-Off Guarantee, participants are offered:
- Support for Sustainable Weight Loss: After completing a 12-month Noom GLP-1Rx program, those who regain weight within 18 months can receive a year of free Noom coaching or substantial discounts on future medication.
- Scientifically Backed Approach: Studies show that weight loss can be maintained after discontinuing GLP-1 medications with a proper behavioral change program. Noom’s comprehensive approach combines medication with lifestyle coaching to empower long-term success.
“Today we are announcing an industry-first: With Noom GLP-1Rx – we are providing both the medications and a pathway off the medications,” said Chief Executive Officer of Noom, Geoff Cook. “We deliver the medications needed to kickstart a weight loss journey and pair it with the psychology-based program needed to sustain that weight loss, and even taper off the med. We view the shortage of GLP-1s to be much worse than the official data suggests. Because the prices of these medications in the U.S. are maintained at such artificially high levels compared to every other large-market country in the world, restricting demand for brand-name meds but increasing demand for compounded meds. We call on policymakers and regulators to take into account this increase in demand and maintain compounding exemptions until the price of the brand-name medications in New York and Los Angeles match their price in London and Sydney. The bottom line is these medications should be $200-$300 a month, not $1300. Policymakers and regulators should demand this or keep the shortage in place to meet the very real demand at these lower prices—the same prices at which these medications are available in the rest of the world. As a longer term solution to address this problem, we also call for bi-partisan legislation to cap drug prices or extend shortages until the brand-name price falls. More supply at a reasonable price is needed right now, not less,” said Cook.